Genomic and Epigenomic Biomarkers of Toxicology and Disease The latest developments in biomarker research applicable to toxicology and medicine Research on genomic and epigenomic biomarkers is developing rapidly with cutting-edge studies scattered throughout the academic literature, making the status of ongoing scientific activity in this area difficult to ascertain. Genomic and Epigenomic Biomarkers of Toxicology and Disease: Clinical and Therapeutic Actions delivers a comprehensive and authoritative compilation of up-to-date developments in the application of genomic and epigenomic biomarkers to toxicology, disease prevention, cancer detection, therapeutics, gene therapy, and other areas. With contributions from a collection of internationally recognized investigators, this edited volume offers unique insights into current trends and future directions of research in the discussed areas. Combining state-of-the-art information on genomic and epigenomic biomarkers from a range of specialists from around the world, this monograph includes: A thorough introduction to microRNAs as non-invasive biomarkers of toxicity and chemical hazard Comprehensive explorations of extracellular vesicle-associated miRNAs as toxic biomarkers, as well as transcriptomic applications in toxicology and medicine Practical discussions of circulating miRNAs as biomarkers of metal exposure, as well as microRNAs biomarkers of malignant mesothelioma In-depth examinations of the role of noncoding RNAs in innate immune responses perturbed by environmental arsenic with a focus on microRNAs Perfect for researchers, toxicologists, risk assessors, and regulators, Genomic and Epigenomic Biomarkers of Toxicology and Disease: Clinical and Therapeutic Actions will also earn a place in the libraries of graduate students with an interest in biomarkers, toxicology, agriculture, or the environment.

This book examines the toxicological and health implications of environmental epigenetics and provides knowledge through an interdisciplinary approach. Included in this volume are chapters outlining various environmental risk factors such as phthalates and dietary components, life states such as pregnancy and ageing, hormonal and metabolic considerations and specific disease risks such as cancer cardiovascular diseases and other non-communicable diseases. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses. Environmental Epigenetics imparts integrative knowledge of the science of epigenetics and the issues raised in environmental epidemiology. This book is intended to serve both as a reference compendium on environmental epigenetics for scientists in academia, industry and laboratories and as a textbook for graduate level environmental health courses.

Impact of Engineered Nanomaterials in Genomics and Epigenomics Overview of current research and technologies in nanomaterial science as applied to omics science at the single cell level Impact of Engineered Nanomaterials in Genomics and Epigenomics is a comprehensive and authoritative compilation of the genetic processes and instructions that specifically direct individual genes to turn on or off, focusing on the developing technologies of engineering nanomaterials and their role in cell engineering which have become important research tools for pharmaceutical, biological, medical, and toxicological studies. Combining state-of-the art information on the impact of engineered nanomaterials in genomics and epigenomics, from a range of internationally recognized investigators from around the world, this edited volume offers unique insights into the current trends and future directions of research in this scientific field. Impact of Engineered Nanomaterials in Genomics and Epigenomics includes detailed information on sample topics such as: Impact of engineered nanomaterials in genomics and epigenomics, including adverse impact on glucose energy metabolism Toxicogenomics, toxicoepigenomics, genotoxicity and epigenotoxicity, and mechanisms of toxicogenomics and toxicoepigenomics Adverse effects of engineered nanomaterials on human environment and metabolomics pathways leading to ecological toxicity Meta-analysis methods to identify genomic toxicity mechanisms of engineered nanomaterials and biological effects of engineered nanomaterial exposure Artificial intelligence and machine learning of single-cell transcriptomics of engineered nanoparticles and trends in plant nano-interaction to mitigate abiotic stresses This comprehensive work is a valuable and excellent source of authoritative and up-to-date information for advanced students and researchers, toxicologists, the drug industry, risk assessors and regulators in academia, industry, and government, as well as for clinical scientists working in hospital and clinical environments.

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

The current exposure of human populations to toxic metals makes the prevention and control of such exposures crucial. Biomarkers are undoubtably recognized as vital tools to achieve these goals. This book is for researchers, toxicologists, physicians, pharmacologists and those working in governmental regulatory agencies and other public health fields. The first part of this book covers general aspects of biomarkers of toxic metals, while parts 2 and 3 cover biomarkers of xenobiotic metals and essential metals with potential for toxicity, respectively. In part 4, novel approaches to metal biomarkers are focused.

Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.

The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.